Brightol

Brightol is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on high-prevalence diseases, particularly in the fields of metabolic disorders, oncology, and inflammatory diseases. Brightol leverages its proprietary drug discovery platform to develop next-generation treatments, including multi-target agonists for metabolic health. Its lead program, BRL-03, is an oral small molecule GLP-1 receptor agonist currently in Phase 1 clinical trials for the treatment of obesity and type 2 diabetes. The company aims to provide more convenient and accessible oral alternatives to existing injectable peptide therapies.